Document Detail


Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
MedLine Citation:
PMID:  20179256     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To describe the use of lubiprostone for constipation in 3 adults with cystic fibrosis (CF).
CASE SUMMARY: This case series describes the use of lubiprostone for the treatment of constipation in 3 adults with CF (mean +/- SD length of therapy 17.3 +/- 1.5 mo). All 3 patients were prescribed lubiprostone 24 microg twice daily after hospitalization for treatment of intestinal obstruction. Patient 1 continues on chronic polyethylene glycol (PEG) 3350 and lubiprostone and has not had a recurrence of obstruction. Patient 2 requires aggressive chronic therapy with PEG 3350, lubiprostone, and methylnaltrexone. She has had 1 recurrence of obstruction. Patient 3 continues with lubiprostone taken several times per week with good control of constipation and no recurrence of obstruction to date. The adverse effect profile has been tolerable in all 3 patients.
DISCUSSION: CF is caused by a genetic mutation resulting in a dysfunctional or absent CF transmembrane conductance regulator that normally functions as a chloride channel. This results in viscous secretions in multiple organ systems including the lungs and intestinal tract. Accumulation of viscous intestinal contents contributes to constipation, which is common among adults with CF and can sometimes lead to intestinal obstruction. Lubiprostone is indicated for chronic constipation and works by activating type 2 chloride channels (ClC-2) in the intestinal tract. Because it utilizes an alternate chloride channel, lubiprostone may be especially effective for constipation in patients with CF.
CONCLUSIONS: Lubiprostone provides an additional option for the treatment of constipation in adults with CF. Its use in the CF population deserves further study.
Authors:
Catherine E O'Brien; Paula J Anderson; Cindy D Stowe
Related Documents :
7484986 - Effects of halfway house placement on retention of patients in substance abuse aftercare.
2505216 - Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with...
1687856 - The effect of chronic alcohol intake on prognosis and outcome in paracetamol overdose.
413896 - Disaccharidase activities in small intestinal mucosa in patients with cystic fibrosis.
4003376 - Early features of primary biliary cirrhosis: an analysis of 85 patients.
2772176 - Small bowel phytobezoars: detection with radiography.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-23
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-04     Completed Date:  2010-05-18     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  577-81     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alprostadil / adverse effects,  analogs & derivatives*,  pharmacology,  therapeutic use
Chloride Channels / drug effects,  metabolism
Constipation / drug therapy*,  etiology
Cystic Fibrosis / complications*,  genetics,  physiopathology
Cystic Fibrosis Transmembrane Conductance Regulator / genetics,  metabolism
Female
Humans
Intestinal Obstruction / drug therapy,  etiology
Male
Recurrence / prevention & control
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Chloride Channels; 126880-72-6/Cystic Fibrosis Transmembrane Conductance Regulator; 7662KG2R6K/lubiprostone; F5TD010360/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cerebral Spinal Fluid Penetration of Tigecycline in a Patient with Acinetobacter baumannii Cerebriti...
Next Document:  Pitavastatin: A New HMG-CoA Reductase Inhibitor(March) (CE).